DK1944322T3 - Behandling af TNFalfa-relaterede sygdomme - Google Patents
Behandling af TNFalfa-relaterede sygdommeInfo
- Publication number
- DK1944322T3 DK1944322T3 DK07150442.7T DK07150442T DK1944322T3 DK 1944322 T3 DK1944322 T3 DK 1944322T3 DK 07150442 T DK07150442 T DK 07150442T DK 1944322 T3 DK1944322 T3 DK 1944322T3
- Authority
- DK
- Denmark
- Prior art keywords
- tnfalfa
- treatment
- related diseases
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39727502P | 2002-07-19 | 2002-07-19 | |
US41108102P | 2002-09-16 | 2002-09-16 | |
US41749002P | 2002-10-10 | 2002-10-10 | |
US45577703P | 2003-03-18 | 2003-03-18 | |
EP03748949A EP1542720A4 (en) | 2002-07-19 | 2003-07-18 | TREATMENT OF DISORDERS IN RELATION TO TNF ALPHA |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1944322T3 true DK1944322T3 (da) | 2015-06-22 |
Family
ID=30773676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07150442.7T DK1944322T3 (da) | 2002-07-19 | 2003-07-18 | Behandling af TNFalfa-relaterede sygdomme |
Country Status (22)
Country | Link |
---|---|
US (16) | US20040126373A1 (da) |
EP (6) | EP1944322B1 (da) |
JP (4) | JP2006506465A (da) |
KR (6) | KR20130001318A (da) |
CN (4) | CN102764436A (da) |
AR (2) | AR040603A1 (da) |
AU (2) | AU2003267999B2 (da) |
BR (1) | BR0312785A (da) |
CA (4) | CA2800126A1 (da) |
DK (1) | DK1944322T3 (da) |
ES (1) | ES2535365T3 (da) |
HK (2) | HK1121463A1 (da) |
IL (4) | IL166280A (da) |
MX (2) | MX342777B (da) |
MY (2) | MY169308A (da) |
NZ (5) | NZ563452A (da) |
PL (3) | PL218992B1 (da) |
PT (1) | PT1944322E (da) |
SI (1) | SI1944322T1 (da) |
TW (3) | TWI354561B (da) |
WO (1) | WO2004009776A2 (da) |
ZA (1) | ZA200500068B (da) |
Families Citing this family (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
BRPI9715219B8 (pt) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
US7115557B2 (en) * | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20060241074A1 (en) * | 2001-08-14 | 2006-10-26 | The General Hospital Corporation | Methods for treatment of pain |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
PL218992B1 (pl) | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
AU2003298015A1 (en) * | 2002-12-05 | 2004-06-30 | Pdl Biopharma, Inc. | Methods of treatment of ulcerative colitis with anti-cd3 antibodies |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
KR101179012B1 (ko) | 2003-03-10 | 2012-09-03 | 니코메드 게엠베하 | 로플루미라스트 신규한 제조 방법 |
CA2523267C (en) | 2003-04-23 | 2013-09-03 | Biovalve Technologies, Inc. | Hydraulically actuated pump for long duration medicament administration |
US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
CA2534474C (en) * | 2003-08-04 | 2014-09-23 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
US7396819B2 (en) * | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
OA13284A (en) * | 2003-11-06 | 2007-01-31 | Corporation Celgene | Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases. |
US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005094210A2 (en) * | 2004-03-12 | 2005-10-13 | The Hartz Mountain Corporation | Multi-action anthelmintic formulations |
TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
US20060046961A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
CN101065137A (zh) * | 2004-09-16 | 2007-10-31 | 加利福尼亚大学董事会 | 用于改善动脉粥样硬化和其它病变的g型多肽和其它剂 |
DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
RU2414236C2 (ru) | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
AU2006224619B2 (en) * | 2005-03-16 | 2012-06-07 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
MX2007013430A (es) * | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
BRPI0610058A2 (pt) | 2005-05-16 | 2010-05-25 | Abbott Biotech Ltd | uso de inibidor de tnf para tratamento da poliartrite erosiva |
AU2012254978C1 (en) * | 2005-05-16 | 2017-06-01 | Abbvie Biotechnology Ltd | Use of TNF inhibitor for treatment of erosive polyarthritis |
WO2007050130A2 (en) * | 2005-06-03 | 2007-05-03 | Biohesion, Inc. | Gold surfaces coated with a thermostable, chemically resistant polypeptide layer and applications thereof |
EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
US7943134B2 (en) * | 2005-08-31 | 2011-05-17 | Academia Sinica | Compositions and methods for identifying response targets and treating flavivirus infection responses |
TWI333959B (en) * | 2005-08-31 | 2010-12-01 | Academia Sinica | Methods and reagents for the analysis and purification of polysaccharides |
RS53055B (en) * | 2005-11-01 | 2014-04-30 | Abbvie Biotechnology Ltd | PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
KR101361376B1 (ko) | 2006-03-30 | 2014-02-10 | 발레리타스 인코포레이티드 | 복합-카트리지 유체 전달 장치 |
EP2004689A4 (en) | 2006-04-05 | 2010-06-02 | Abbott Biotech Ltd | PURIFICATION OF ANTIBODIES |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2012824A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USE AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS |
WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
EP2021016B1 (en) * | 2006-04-21 | 2016-01-06 | Janssen Biotech, Inc. | Cxcl-13 antagonists and tnf-alpha antagonists for use in a combination therapy |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
KR101396797B1 (ko) * | 2006-06-30 | 2014-05-26 | 애브비 바이오테크놀로지 리미티드 | 자동 주사 장치 |
KR20150002896A (ko) * | 2006-10-27 | 2015-01-07 | 애브비 바이오테크놀로지 리미티드 | 결정형 항-hTNF알파 항체 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CN101200465B (zh) * | 2006-12-11 | 2010-12-29 | 和记黄埔医药(上海)有限公司 | 一种十氢化萘类化合物及其医药用途 |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
CN101679507A (zh) | 2007-03-29 | 2010-03-24 | 艾博特公司 | 结晶抗人类il-12抗体 |
US20080254011A1 (en) * | 2007-04-11 | 2008-10-16 | Peter Rothschild | Use of selected lactic acid bacteria for reducing atherosclerosis |
WO2008141511A1 (fr) * | 2007-05-22 | 2008-11-27 | Human Antibodomics (Shanghai) Inc. | ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION |
WO2008150491A2 (en) * | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
CA2693771A1 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
US7919250B2 (en) * | 2007-07-31 | 2011-04-05 | New York University | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
RU2010107994A (ru) * | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
JP2010538005A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
WO2009052140A1 (en) * | 2007-10-15 | 2009-04-23 | Alcon Research, Ltd. | Use of tnf receptor antagonists for treating dry eye |
WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
SG10201604258YA (en) | 2007-11-30 | 2016-07-28 | Abbvie Biotechnology Ltd | Anti-tnf antibody formulations |
US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
CA2710333A1 (en) * | 2008-01-03 | 2009-07-09 | Abbott Biotechnology Ltd. | Predicting long-term efficacy of a compound in the treatment of psoriasis |
SG2013054218A (en) | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
US9365644B2 (en) * | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
EP2921501A1 (en) * | 2008-10-20 | 2015-09-23 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
EP2918602A1 (en) * | 2009-04-16 | 2015-09-16 | AbbVie Biotherapeutics Inc. | Anti-TNF-alpha antibodies and their uses |
WO2010127146A1 (en) | 2009-04-29 | 2010-11-04 | Abbott Biotechnology Ltd | Automatic injection device |
SG175188A1 (en) * | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
JP5940981B2 (ja) | 2009-12-15 | 2016-06-29 | アッヴィ バイオテクノロジー リミテッド | 自動注射装置のための改善された作動ボタン |
WO2011084714A2 (en) * | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
ES2727275T3 (es) | 2010-04-21 | 2019-10-15 | Abbvie Biotechnology Ltd | Dispositivo automático de inyección portátil para la liberación controlada de agentes terapéuticos |
ES2685607T3 (es) | 2010-06-03 | 2018-10-10 | Abbvie Biotechnology Ltd | Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS) |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
PL2637690T3 (pl) | 2010-11-11 | 2017-03-31 | Abbvie Biotechnology Ltd | Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu |
EP3187216B1 (en) | 2011-01-24 | 2019-08-21 | AbbVie Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
WO2012121988A2 (en) * | 2011-03-07 | 2012-09-13 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
JP6031510B2 (ja) * | 2011-04-12 | 2016-11-24 | モイライ マトリックス インコーポレイテッド | 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法 |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013041246A1 (en) * | 2011-09-23 | 2013-03-28 | Westfälische Wilhelms-Universitaet Muenster | Yersinia outer protein m (yopm) in the treatment of psoriasis |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
CN104394881B (zh) | 2012-06-21 | 2016-10-26 | 韩诺生物制药株式会社 | 修饰的人肿瘤坏死因子受体-1多肽的新用途 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014035475A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
JP2016503397A (ja) * | 2012-10-22 | 2016-02-04 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 心不全関連リスクおよびそれらと関連する因子を減少させる方法 |
US20140255403A1 (en) * | 2013-03-06 | 2014-09-11 | Hadasit Medical Research Services & Development Ltd. | Oral composition comprising a tnf antagonist and use thereof |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
RU2015144149A (ru) | 2013-03-15 | 2017-04-21 | Интермьюн, Инк. | Протеомные маркеры илф |
TWI516272B (zh) * | 2013-06-05 | 2016-01-11 | 財團法人工業技術研究院 | 應用於生髮之方法及醫藥組成物 |
CN104341502B (zh) * | 2013-08-09 | 2016-04-27 | 北京天成新脉生物技术有限公司 | 低免疫原性抗TNF-α全人源单抗及其应用 |
PL226431B1 (pl) | 2013-08-23 | 2017-07-31 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
AU2014337263B2 (en) | 2013-10-16 | 2019-12-12 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CN103961694A (zh) * | 2014-04-18 | 2014-08-06 | 陶惠人 | 基于p-硝基苯丙氨酸***法构建的骨质疏松疫苗 |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
US10351621B2 (en) | 2014-06-24 | 2019-07-16 | Immunomedics, Inc. | Anti-histone therapy in acute kidney injury |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
BR112017001860A2 (pt) | 2014-07-31 | 2018-02-27 | Uab Research Foundation | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal |
CN108064308B (zh) * | 2014-11-05 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 细菌中产生双链蛋白的方法 |
RU2739500C2 (ru) | 2014-11-05 | 2020-12-25 | Дженентек, Инк. | Способы получения двуцепочечных белков в бактериях |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3227880B1 (en) * | 2014-12-01 | 2018-09-26 | Truinject Corp. | Injection training tool emitting omnidirectional light |
EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
EP3255994B1 (en) | 2015-02-03 | 2020-04-08 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating arthritis |
EP3277719B1 (en) | 2015-03-31 | 2022-03-16 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
AU2016275149A1 (en) | 2015-06-12 | 2018-01-04 | Georgia State University Research Foundation | Compositions and methods for treating opioid tolerance |
CN105175529A (zh) * | 2015-07-16 | 2015-12-23 | 中国科学院海洋研究所 | 一种鱼类肿瘤坏死因子家族蛋白的重组蛋白及其应用 |
JP2018527903A (ja) * | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Gdf11結合タンパク質およびその使用 |
CN113896789A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
CN109563161A (zh) | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
US10465003B2 (en) * | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
PT3368069T (pt) | 2016-06-13 | 2020-11-11 | Scholar Rock Inc | Uso de inibidores da miostatina e terapias de combinação |
USD802756S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
WO2018045213A1 (en) * | 2016-09-02 | 2018-03-08 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
WO2018045258A1 (en) * | 2016-09-02 | 2018-03-08 | The University Of Chicago | TREATMENT OF TNF-alpha CYTOTOXICITY |
WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
US20180110856A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
MX2019006864A (es) * | 2016-12-14 | 2019-10-15 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf). |
EP4218817A3 (en) | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
EP3616738B1 (en) * | 2017-04-25 | 2023-06-21 | CC Biotechnology Corporation | Injection pen |
KR101946884B1 (ko) * | 2017-04-25 | 2019-02-13 | 고려대학교 산학협력단 | 대사체 분석을 이용한 베체트병의 진단방법 |
JP7414529B2 (ja) | 2017-06-07 | 2024-01-16 | シファメド・ホールディングス・エルエルシー | 血管内流体移動デバイス、システム、および使用方法 |
KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
WO2019094963A1 (en) | 2017-11-13 | 2019-05-16 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
US10722631B2 (en) | 2018-02-01 | 2020-07-28 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
CN108588040B (zh) * | 2018-06-08 | 2021-06-15 | 中国医学科学院病原生物学研究所 | 重组MtMetRS、其晶体及它们在制备抗结核药物中的应用 |
US20210347881A1 (en) * | 2018-07-25 | 2021-11-11 | Rush University Medical Center | Inhibition of kidney disease relapse by targeted cytokine depletion |
JP7254916B2 (ja) | 2018-10-26 | 2023-04-10 | アボット ダイアベティス ケア インコーポレイテッド | 生理学的パラメータ分析のための方法、デバイスおよびシステム |
CN109998488B (zh) * | 2019-04-13 | 2022-08-02 | 中国医学科学院北京协和医院 | 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法 |
BR112021025416A2 (pt) * | 2019-06-17 | 2022-02-22 | Mayo Found Medical Education & Res | Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares |
US20220242945A1 (en) | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
WO2021011473A1 (en) | 2019-07-12 | 2021-01-21 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
CA3149049A1 (en) * | 2019-08-30 | 2021-03-04 | Vestlandets Innovasjonsselskap As | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells |
US11724089B2 (en) | 2019-09-25 | 2023-08-15 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合TGF-α及表皮調節素(EPIREGULIN)之抗體於治療疼痛之用途 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448A (en) | 1849-05-15 | Improvement in cut-offs and steam-stops of rotary engines | ||
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US6451983B2 (en) * | 1989-08-07 | 2002-09-17 | Peptech Limited | Tumor necrosis factor antibodies |
US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
FR2651130B1 (fr) * | 1989-08-23 | 1991-12-13 | Roussel Uclaf | Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques. |
WO1991003553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | TUMOR NECROSIS FACTOR-α AND -β RECEPTORS |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US20070298040A1 (en) * | 1991-03-18 | 2007-12-27 | Centocor, Inc. | Methods of treating seronegative arthropathy with anti-TNF antibodies |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
DK1097945T3 (da) * | 1991-03-18 | 2007-11-05 | Univ New York | Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor |
US20060246073A1 (en) * | 1991-03-18 | 2006-11-02 | Knight David M | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
AU3924993A (en) | 1992-04-02 | 1993-11-08 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
PT614984E (pt) * | 1993-03-05 | 2001-12-28 | Bayer Ag | Anticorpos humanos anti-tnf |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
AU1738497A (en) * | 1996-02-08 | 1997-08-28 | Warwick Andrew Mckenzie | Lockable coupling |
BRPI9715219B8 (pt) | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
ES2168581T3 (es) * | 1996-06-27 | 2002-06-16 | Pfizer | Derivados de indazol sustituidos. |
ATE242234T1 (de) * | 1996-11-15 | 2003-06-15 | Darwin Discovery Ltd | Bicyclische arylcarboxamide und ihre therapeutische verwendung |
CA2290021A1 (en) * | 1997-05-12 | 1998-11-19 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
JPH11127882A (ja) * | 1997-10-27 | 1999-05-18 | Nippon Kayaku Co Ltd | 新規生理活性物質nk30424a,nk30424b,それらの製造法およびそれらの用途 |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
US6537549B2 (en) * | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
ATE245152T1 (de) * | 1999-03-31 | 2003-08-15 | Pfizer Prod Inc | Dioxocyclopentylhydroxamsäure |
US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
WO2001037874A2 (en) * | 1999-11-24 | 2001-05-31 | Centocor, Inc. | Treatment of psoriasis by using an antibody to tnf alpha |
JP4812921B2 (ja) * | 2000-04-14 | 2011-11-09 | 田辺三菱製薬株式会社 | ベーチェット病治療剤 |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
EP1345968A2 (en) * | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
WO2002096461A1 (en) * | 2001-05-25 | 2002-12-05 | Abbott Gmbh & Co. Kg | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
PL218992B1 (pl) | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
KR20050086628A (ko) * | 2002-11-15 | 2005-08-30 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
US20040193466A1 (en) * | 2003-03-27 | 2004-09-30 | Irena Kull | Method and process for managing a yard |
TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
BRPI0610058A2 (pt) * | 2005-05-16 | 2010-05-25 | Abbott Biotech Ltd | uso de inibidor de tnf para tratamento da poliartrite erosiva |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
RS53055B (en) * | 2005-11-01 | 2014-04-30 | Abbvie Biotechnology Ltd | PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS |
EP2004689A4 (en) * | 2006-04-05 | 2010-06-02 | Abbott Biotech Ltd | PURIFICATION OF ANTIBODIES |
WO2007120626A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
EP2010214A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
EP2666472A3 (en) * | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
KR101396797B1 (ko) * | 2006-06-30 | 2014-05-26 | 애브비 바이오테크놀로지 리미티드 | 자동 주사 장치 |
WO2008033517A2 (en) * | 2006-09-13 | 2008-03-20 | Abbott Laboratories | Cell culture improvements |
KR20150002896A (ko) * | 2006-10-27 | 2015-01-07 | 애브비 바이오테크놀로지 리미티드 | 결정형 항-hTNF알파 항체 |
WO2008150491A2 (en) * | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
WO2008150490A2 (en) * | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
US8999337B2 (en) * | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
CA2693771A1 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
RU2010107994A (ru) * | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
SG10201604258YA (en) * | 2007-11-30 | 2016-07-28 | Abbvie Biotechnology Ltd | Anti-tnf antibody formulations |
CA2710333A1 (en) * | 2008-01-03 | 2009-07-09 | Abbott Biotechnology Ltd. | Predicting long-term efficacy of a compound in the treatment of psoriasis |
SG2013054218A (en) * | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
AU2009206089B2 (en) * | 2008-01-15 | 2014-08-28 | Abbvie Inc. | Improved mammalian expression vectors and uses thereof |
CA2717905A1 (en) * | 2008-03-24 | 2009-10-01 | Abbott Biotechnology Ltd. | Methods and compositions for treating bone loss |
WO2010083042A1 (en) * | 2009-01-15 | 2010-07-22 | Manta Devices, Llc | Delivery device |
WO2010127146A1 (en) * | 2009-04-29 | 2010-11-04 | Abbott Biotechnology Ltd | Automatic injection device |
SG175188A1 (en) * | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
-
2003
- 2003-07-18 PL PL401886A patent/PL218992B1/pl unknown
- 2003-07-18 KR KR1020127030281A patent/KR20130001318A/ko not_active IP Right Cessation
- 2003-07-18 PT PT71504427T patent/PT1944322E/pt unknown
- 2003-07-18 ES ES07150442.7T patent/ES2535365T3/es not_active Expired - Lifetime
- 2003-07-18 TW TW092119891A patent/TWI354561B/zh not_active IP Right Cessation
- 2003-07-18 TW TW101135423A patent/TWI527592B/zh not_active IP Right Cessation
- 2003-07-18 NZ NZ563452A patent/NZ563452A/en not_active IP Right Cessation
- 2003-07-18 US US10/623,065 patent/US20040126373A1/en not_active Abandoned
- 2003-07-18 MY MYPI2013004323A patent/MY169308A/en unknown
- 2003-07-18 EP EP07150442.7A patent/EP1944322B1/en not_active Revoked
- 2003-07-18 CN CN2012102392802A patent/CN102764436A/zh active Pending
- 2003-07-18 KR KR1020127001635A patent/KR101283877B1/ko active IP Right Review Request
- 2003-07-18 EP EP15157149.4A patent/EP2942359A1/en not_active Withdrawn
- 2003-07-18 AU AU2003267999A patent/AU2003267999B2/en not_active Expired
- 2003-07-18 US US10/623,318 patent/US20130243786A1/en not_active Abandoned
- 2003-07-18 MX MX2009003691A patent/MX342777B/es unknown
- 2003-07-18 CN CN200910253363A patent/CN101745112A/zh active Pending
- 2003-07-18 MY MYPI20032713 patent/MY151032A/en unknown
- 2003-07-18 WO PCT/US2003/022566 patent/WO2004009776A2/en active Application Filing
- 2003-07-18 US US10/623,039 patent/US20070202104A1/en not_active Abandoned
- 2003-07-18 US US10/623,035 patent/US20040136990A1/en not_active Abandoned
- 2003-07-18 EP EP10182274A patent/EP2336182A1/en not_active Ceased
- 2003-07-18 NZ NZ598346A patent/NZ598346A/xx not_active IP Right Cessation
- 2003-07-18 KR KR1020057001064A patent/KR20050042466A/ko not_active Application Discontinuation
- 2003-07-18 CA CA2800126A patent/CA2800126A1/en not_active Abandoned
- 2003-07-18 US US10/623,076 patent/US20040131614A1/en not_active Abandoned
- 2003-07-18 TW TW098127343A patent/TWI430810B/zh not_active IP Right Cessation
- 2003-07-18 KR KR20157009634A patent/KR20150043568A/ko not_active Application Discontinuation
- 2003-07-18 AR AR20030102605A patent/AR040603A1/es not_active Application Discontinuation
- 2003-07-18 NZ NZ587754A patent/NZ587754A/en not_active IP Right Cessation
- 2003-07-18 US US10/622,928 patent/US20040151722A1/en not_active Abandoned
- 2003-07-18 US US10/622,210 patent/US20040136989A1/en not_active Abandoned
- 2003-07-18 CN CN2012102392380A patent/CN102755646A/zh active Pending
- 2003-07-18 NZ NZ555692A patent/NZ555692A/en not_active IP Right Cessation
- 2003-07-18 CA CA002493067A patent/CA2493067A1/en not_active Abandoned
- 2003-07-18 CA CA2803741A patent/CA2803741A1/en not_active Withdrawn
- 2003-07-18 US US10/622,932 patent/US20040126372A1/en not_active Abandoned
- 2003-07-18 CA CA2880296A patent/CA2880296A1/en not_active Abandoned
- 2003-07-18 MX MXPA05000815A patent/MXPA05000815A/es active IP Right Grant
- 2003-07-18 KR KR1020147007746A patent/KR20140058649A/ko not_active Application Discontinuation
- 2003-07-18 EP EP10182730A patent/EP2371859A3/en not_active Withdrawn
- 2003-07-18 BR BR0312785-0A patent/BR0312785A/pt not_active Application Discontinuation
- 2003-07-18 PL PL374865A patent/PL213925B1/pl unknown
- 2003-07-18 DK DK07150442.7T patent/DK1944322T3/da active
- 2003-07-18 US US10/622,205 patent/US20040219142A1/en not_active Abandoned
- 2003-07-18 JP JP2005505532A patent/JP2006506465A/ja not_active Withdrawn
- 2003-07-18 SI SI200332414T patent/SI1944322T1/sl unknown
- 2003-07-18 US US10/623,075 patent/US20040136991A1/en not_active Abandoned
- 2003-07-18 CN CNA038224550A patent/CN1691963A/zh active Pending
- 2003-07-18 PL PL397846A patent/PL217223B1/pl unknown
- 2003-07-18 EP EP10183702A patent/EP2298810A3/en not_active Withdrawn
- 2003-07-18 EP EP03748949A patent/EP1542720A4/en not_active Withdrawn
- 2003-07-18 KR KR1020117004851A patent/KR20110027851A/ko not_active Application Discontinuation
-
2005
- 2005-01-04 ZA ZA2005/00068A patent/ZA200500068B/en unknown
- 2005-01-13 IL IL166280A patent/IL166280A/en active IP Right Grant
- 2005-12-21 HK HK09100383.6A patent/HK1121463A1/xx not_active IP Right Cessation
-
2008
- 2008-04-14 US US12/102,682 patent/US20080193466A1/en not_active Abandoned
-
2009
- 2009-05-06 NZ NZ576774A patent/NZ576774A/en not_active IP Right Cessation
-
2010
- 2010-02-25 AU AU2010200708A patent/AU2010200708B2/en not_active Expired
- 2010-03-15 JP JP2010057713A patent/JP2010209070A/ja active Pending
- 2010-07-14 AR ARP100102563A patent/AR077474A2/es not_active Application Discontinuation
- 2010-12-19 IL IL210091A patent/IL210091A/en active IP Right Grant
- 2010-12-19 IL IL210090A patent/IL210090A0/en unknown
-
2011
- 2011-06-06 IL IL213400A patent/IL213400A0/en unknown
-
2012
- 2012-10-11 JP JP2012225755A patent/JP2013056892A/ja not_active Withdrawn
-
2013
- 2013-05-28 US US13/903,525 patent/US20130243763A1/en not_active Abandoned
-
2014
- 2014-05-02 US US14/268,449 patent/US20140286939A1/en not_active Abandoned
- 2014-05-02 US US14/268,614 patent/US20140286940A1/en not_active Abandoned
- 2014-05-02 US US14/268,628 patent/US20140286941A1/en not_active Abandoned
-
2015
- 2015-06-09 JP JP2015116695A patent/JP2015221798A/ja active Pending
- 2015-09-03 US US14/844,578 patent/US20150368335A1/en not_active Abandoned
-
2016
- 2016-03-18 HK HK16103196.8A patent/HK1215265A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1944322T3 (da) | Behandling af TNFalfa-relaterede sygdomme | |
CY2016035I2 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
FR15C0028I2 (fr) | Fabrication de tiacumicine | |
FI20060154A (fi) | Neurogeneratiivisten tilojen hoito | |
DK1663287T3 (da) | Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme | |
DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
DE60312780D1 (de) | Wegwerfwindel | |
DK1701941T3 (da) | Forbindelser til behandling af sygdomme med celleproliferation | |
DK1556342T3 (da) | Phenethanolaminderivat til behandling af respiratoriske sygdomme | |
NO20052914D0 (no) | Terapeutiske forbindelser | |
DE602004018587D1 (de) | Staubschützende Wegwerfmaske | |
DK2308507T3 (da) | Fremgangsmåder til behandling af præeklampsi | |
DE60336213D1 (de) | Chirurgisches klammergerät | |
DE60311298D1 (de) | Kopfhautbehandlung | |
DK1744781T3 (da) | Behandling af infektionssygdomme | |
DK1448205T3 (da) | Kombinationer til behandling af immunoinflammatoriske sygdomme | |
NO20050689L (no) | Terapeutisk anvendelse | |
IS7825A (is) | Meðferðarfræðileg meðhöndlun | |
DK1487828T3 (da) | Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme | |
DK1812002T3 (da) | Behandling af mastitis | |
DE60236743D1 (de) | Zur behandlung androgenabhängiger krankheiten | |
DK1727801T3 (da) | Til behandling af smerter anvendelige piperaziner | |
DK1597171T3 (da) | Terapeutisk mikroskum | |
DE602004004262D1 (de) | Ultraschallbehandlung von gewebematrices | |
DK1687297T3 (da) | Triazindimerer til behandling af autoimmunsygdomme |